大连医科大学附属第一医院

宁振(普外)

宁振(普外)
所属科室:
外科学
职称:
副主任医师
出诊时间:
专家介绍:
宁振,乳腺外科副主任医师,外科学博士,分析化学博士后,硕士研究生导师。目前担任中国临床肿瘤学会(CSCO)肿瘤心脏病学专业委员会委员、中国妇幼健康研究会乳腺癌防治研究专委会委员、辽宁省生命科学学会乳房修复重建与美容专委会委员、辽宁省抗癌协会肿瘤中西医结合专委会委员、辽宁省生命科学学会肝胆胰外科及数字医学分会青委会副主任委员、大连肿瘤学会委员等学术任职。研究方向:1、乳腺癌、肝胆胰肿瘤的代谢重编程调控机制;2、肿瘤心脏病学研究。科研课题:主持国家自然基金青年基金1项,主持中国博士后面上基金(一等)1项,参与国家自然科学基金及辽宁省重点研发计划多项。以第一作者或通讯作者在Nature Communications、Oncogene、Cancer letters、中华外科杂志等发表文章30余篇。获评2019年度大连市青年科技之星,获辽宁省科技进步二等奖、辽宁医学科技三等奖、大连市科技进步二等奖各1项。申请发明专利1项。 代表论文: 1. Ning Z#, Guo X#, Liu X#, Lu C#, Wang A, Wang X, Wang W, Chen H, Qin W, Liu X, Zhou L, Ma C, Du J, Lin Z, Luo H, Otkur W, Qi H, Chen D, Xia T, Liu J, Tan G*, Xu G*, Piao HL*. USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma. Nat Commun. 2022 Apr 21;13(1):2187. 第一作者 IF:16.6 2. Chen D#, Ning Z#, Chen H#, Lu C#, Liu X, Xia T, Qi H, Wang W, Ling T, Guo X, Tekcham DS, Liu X, Liu J, Wang AM, Yan Q, Liu JW*, Tan G*, Piao HL*. An integrative pan-cancer analysis of biological and clinical impacts underlying ubiquitin-specific-processing proteases. Oncogene. 2020 Jan;39(3):587-602. 第一作者 IF:9.867 3. Lu C#, Ning Z#, Wang A#, Chen D#, Liu X, Xia T, Tekcham DS, Wang W, Li T, Liu X, Liu J, Qi H, Luo H, Du J, Ma C, Yan Q, Liu J, Xu G, Piao HL*, Tan G*. USP10 suppresses tumor progression by inhibiting mTOR activation in hepatocellular carcinoma. Cancer Lett. 2018 Nov 1; 436:139-148.第一作者 IF:9.1 4. Qin HN#, Teng YB#, Yu PY, Wang AM, Ning Z*, Liu JW*. Cardiovascular adverse events associated with EGFR and HER2 dual TKIs: a pharmacovigilance study based on the FAERs database. Expert Opin Drug Saf. 2025. 通讯作者 IF:3.0 5. Sun R#, Ning Z#, Qin H, Zhang W, Teng Y, Jin C, Liu J*, Wang A*. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database. Sci Rep. 2024 Apr 25;14(1):9552. 通讯作者 IF:4.6 6. Qin HN#, Sun R#, Guo X#, Fang L, Xu MY, Teng YB, Ning Z*, Wang AM*, Liu JW*. RIOK3 promotes mTORC1 activation by facilitating SLC7A2-mediated arginine uptake in pancreatic ductal adenocarcinoma. Aging (Albany NY). 2023 Feb 24;15(4):1039-1051. 通讯作者 IF:5.955 7. Ning Z#, Xu G*. Can spatially resolved metabolomics uncover weak points in tumors? Expert Rev Proteomics. 2023 Feb 6. 2022 Apr-Jun;19(4-6):227-230. 第一作者 IF:3.8 8. Qin HN#, Ning Z#, Sun R#, Jin CX, Guo X, Wang AM*, Liu JW*. Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis. Front Oncol. 2022 Nov 22;12:1003426. 第一作者 IF:5.738 9. Lin Z#, Ma C#, Cao W, Ning Z*, Tan G*. Prognostic significance of NLR, PLR, LMR and tumor infiltrating T lymphocytes in patients undergoing surgical resection for Hilar Cholangiocarcinoma. Front Oncol. 2022 Jun 3;12:908907. 第一作者 IF:5.738 10. Xu MY#, Fang L#, Guo X#, Qin HN, Sun R, Ning Z*, Wang A*. RIOK3 promotes pancreatic ductal adenocarcinoma cell invasion and metastasis by stabilizing FAK. Heliyon. 2022 Aug 3;8(8):e10116. 通讯作者 IF:3.776